InxMed

Invent Individualized Medicine with International Impact

InxMed is a clinical-stage biotech company focus on “Best-in-Disease Combination Strategy”. With disease biology as the source of innovation, InxMed is committed to building a platform with fast clinical transformation and proof-of-concept capability, and becoming a global leading company from China in the 2.0 era of new drug R&D.

More

News传递优秀的企业文化,专注医学,回馈社会

Interview of Zaiqi Wang – Chairman & CEO, InxMed by PharmaBoardroom

Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.
2020-08-26

InxMed Released Research Data of “FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition” at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,
2020-06-24

InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States

Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
2020-03-17

InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab January 07, 2020

Shanghai, China – InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company
2020-01-07

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018

Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the Company has obtained IND (Investigational New Drug) clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor, from China National Medical Products Administration (NMPA) to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer. Previously IN10018 has opened IND in the United States in August 2019.
2019-12-20

Our TeamMembers of the InxMed core team have held senior R&D and management positions in top-ranking MNC companies such as Roche, Novartis, MSD, Schering-Plough, GlaxoSmithKline and Johnson & Johnson, who led teams to complete clinical development and registration of a dozen drugs, including Keytruda, Gardasil in China, having rich experience in all aspects of innovative drug research, development, clinical transformation, proof-of-concept, and marketing.

Team


PipelineWe are building up a differentiated pipeline with potential of intrinsic synergy to combat cancer. We are exploring varies of combinational use to maximize the value of each asset and generate impactful treatment regimens for cancer patients.

PartneringPartnering with the best early stage science and clinical-stage programs is our top priority. We are dedicated to building strong partnership with top-tier research institutes, biotech and pharmaceutical companies. Our initial focus is to partner with assets with potential synergy with our current portfolio to enable us to select the winning combination and deliver meaningful benefit in the fight against cancer.

InxMed

Copyright © 2019  InxMed  ICP备10238728号  Powered by 300.cn